Results Press Release
Cadila Healthcare Ltd has submitted to BSE a copy of Results Press Release for the period ended December 31, 2015.05-02-2016
05-02-2016
Announces Q3 Results (Standalone & Consolidated), Limited Review Report (Standalone) for the Quarter ended December 31, 2015
Cadila Healthcare Ltd has announced the following results for the quarter ended December 31, 2015 :The Un-Audited Standalone results for the Quarter ended December 31, 2015The Company has posted a net profit of Rs. 4695 million for the quarter ended December 31, 2015 as compared to Rs. 3612 million for the quarter ended December 31, 2014. Total Income has increased from Rs. 14751 million for the quarter ended December 31, 2014 to...05-02-2016
Shareholding for the Period Ended December 31, 2015
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here23-01-2016
Q3 results on Feb 05, 2016
Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 05, 2016, inter alia, to consider & approve the un-audited financial results for the quarter/ nine months ended December 31, 2015 (Q3).Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window shall remain closed...20-01-2016
Cadila gets nod for Rs 5,000-cr QIP
FIPB has approved a total investment proposal of Rs 6,050 cr, with the largest chunk coming from Cadila Healthcare and Nitin Lifesciences14-01-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Cadila Healthcare Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.13-01-2016
Cadila Healthcare gets EIR report from USFDA
Establishment Inspection Report is given to an establishment after the completion of the inspection by the FDA11-01-2016
Zydus' Baddi Plant successfully obtains the Establishment Inspection Report from the USFDA
Cadila Healthcare Ltd has informed BSE that "Our state-of-the-art manufacturing plant at Baddi, Himachal Pradesh, has successfully obtained the Establishment Inspection Report from the USFDA. This will now pave the way for further approval of products from this site".11-01-2016
USFDA alleges Cadila's 2 plants for violating CGMP regulations
Torn notebook with record of 'deficiencies', plastic bags filled with shreds of paperwork, failure to adequately investigate and address consumer complaints, are some of the major norm violations found by the USFDA at Cadila Healthcare's two plants in Gujarat.06-01-2016
Zydus expands animal health business with a strategic acquisition
Cadila Healthcare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 05, 2016, approved the proposal to expand its animal health business with a strategic acquisition.In this regard, the Company has issued a Press Release dated January 05, 2016, titled "Zydus expands animal health business with a strategic acquisition".05-01-2016